Waldencast plc said its Obagi Medical unit has partnered with Schweiger Dermatology in the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program to generate real-world evidence for Obagi saypha MagIQ, a hyaluronic acid injectable developed by Croma-Pharma GmbH. The collaboration includes a Phase 4 clinical study led by Dr. David Goldberg at Schweiger’s Hackensack location with standardized data capture, as well as a real-world evaluation program at select Schweiger aesthetic sites to assess use alongside Obagi protocols. Initial program activities are expected to begin in early 2026, and results are planned to be presented in the future at internal leadership meetings and at industry conferences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602270833PRIMZONEFULLFEED9662675) on February 27, 2026, and is solely responsible for the information contained therein.